Published in JAMA Neurology · View the paper (DOI)
Researchers have discovered that low levels of N-acetylglucosamine are associated with progressive MS, clinical disability and neurodegeneration. The simple sugar may serve as a biomarker and promote myelin repair, offering potential new avenues for treating the disease.
Coverage from 2 institutions